Preparent Standard Panel

Size: px
Start display at page:

Download "Preparent Standard Panel"

Transcription

1 Preparent Standard Panel Disorder Gene Variants Ethnicity Alpha-thalassemia HBA1 HBA2 -alpha3.7, -alpha4.2, -alpha20.5, --SEA, --MED, --FIL, --THAI Mediterranean 1 in 20 1 in in 291 African American 1 in in 4,991 Beta-thalassemia HBB 118C>T, 126_129delCTTT, 135delC, -138C>T, 22_24delGAG, 25_26delAA, 27dupG, 315+1G>A, 316-2A>C, 316-2A>G, 47G>A, 51delC, 52A>T, 59A>G, 75T>A, -78A>G/-28A>G, -79A>G/-29A>G, 93-1G>A, 93-21G>A Mediterranean South Southeast East 1 in 20 1 in 20 1 in 50 80% 29% 69% 71% 74% 1 in 96 1 in 28 1 in 95 1 in 112 African American 1 in 50 1 in 75 1 in 80 37% 85% 80% 1 in 79 1 in in 396 Bloom syndrome BLM 2281Del6/Ins7, 2407dupT Ashkenazi Jewish 1 in in 9,901 Canavan disease ASPA IVS2-2A>G, p.a305e, p.e285a, p.y231x, p.y288c Ashkenazi Jewish 1 in 41 98% 1 in 2,001 1 in % 1 in 328 Congenital amegakaryocytic thrombocytopenia MPL IVS1+2T>A Ashkenazi Jewish 1 in 75 1 in 7,401 Cystic fibrosis (600 mutations) CFTR R347P; Y122X; 852del22; S549R; S1255X; L1077P; G->A; G->A; 711+1G->T; G>A; 4016insT; Q1313X; 4209TGTT>AA; 4382delA; 2143delT; L1065P; R1066C; R1066H; R117C; L467P; 1548delG; S489X; S492F; 3821delT; Q179K; M1101K; E1104X; Y1092X; R117H; PolyT 5T/7T/9T; 574delA; 663delT; G178R; 711+3A>G; 711+5G>A; 712-1G>T; H199Y; P205S; L206W; Q220X; R334W; 935delA; A455E; 1078delT; G330X; I336K; T338I; S341P; 1154insTC; R347H; R352Q; 1213delT; G>A; 1259insA; W401X; W401X; G>A; 1461ins4; G>A; F508C; 1677delTA; V520F; G542X; 621+1G->T; [delta]f311; [delta]f508; S466X; G551D; G->A; R553X; R560T; S549N; Q552X; S549R; A559T; R560K; kbA->G; G->A; Y569D; I507V; E585X; G->C; A>G; 2184delA; 2184insA; R709X; K710X; 2307insA; L732X; 2347delG; G>A; R764X; 2585delT; E822X; G>A; E831X; W846X; R851X; 2711delT; Q890X; L927P; S945L; 3007delG; G970R; 3120G>A; Ashkenazi Jewish African American 1 in 24 1 in 25 1 in 58 1 in 61 1 in % 82% 56% -- 1 in 2,301 1 in in in in S. State Road, Ann Arbor, MI Tel Fax progenity.com Page 1 of 8

2 3121-1G->A; 3171delC; 3199del6; G->A; A->G; 394delTT ; D1152H; R1158X; R1162X; 3659delC; W1282X; S1196X; 3791delC; N1303K; N1303K; W1204X; W1204X; S1255X; G1244E; 3876delA; S1251N; 3905insT; kbC->T; CFTRdele22.23; 444delA; 457TAT->G; S466X; Y1092X; [delta]i507; 2183delAA>G; M1V; G85E; Q39X; 406-1G->A; E60X; P67L; R75X; 405+1G>A; E92X; E92K; Q98X; D110H; W1089X; CFTRdele2.3; 1949del84; Q493X; G->A; I506V(1648A/G); G->T; W361X; 681delC; 1367delC; 1367del5; 1460delAT; 1471delA; 1353_1354insT; 1504delG; 1540del10; 1565 del CA; 1571delG; 1576insT; 1469delT; 1601delTC; 1660delG; 1742delAC; 1749insTA; 1774delCT; Y325X; R792X; L558X; G1003X; Y161X; 412del7- >TA; H1054D; G1061R; 3532AC- >GTA; F1074L; Y28X; R29X; E33X; 3960_3961delA; L34X; S35X; S35X; K114X; W277X; G404X; W882X; S912X; S1206X(C>A); S1206X (C>G); L1254X; W1274X; Q1281X; Q1291X; Y1307X; E1308X; W1310X; W1316X; E1371X; R532X; E535X; M1L; K536X; A46D; 297-1G>A; G551S; E543X; G545X; R555X; L558X; Y563X; K564X; L90X; L94X; L101X; G366X; K370X; L375X; Q376X; K377X; Q378X; Y380X; K381X; L383X; E384X; Y385X; Y385X; L387X; L387X; E391X; E395X; E402X; E403X; E407X; L408X; L408X; E410X; K411X; K447X; E449X; R450X; G451X; Q452X; L453X; L454X; G458X; G461X; G473X; E476X; S478X; S478X; K481X; K483X; R487X; C491X; K503X; Y512X; E514X; R516X; 547insTA; 556delA ; 557delT; 565delC; 605insT; 657delA; K442X; 1782delA; Q353X; 2948AT- >C; 3079delTT; 3293delA; 3126del4; 3132delTG; 3171insC; 3173delAC; 3200_3204delTAGTG; 3238delA; 3180delA; 3320ins5; 3359delCT; 3263dupA; 3396delC; 3419delT; 3423delC; 3425delG; 3447delG; 3855delC; 3577delT; 3617delGA; 3622insT; 3629delT; 3662delA; 3667ins4; 3670delA; 3724delG; 3737delA; 3750delAG; 3755delG; 3789insA; 3708delT; 3878delG; 3898insC; 3906insG; 3944delGT; 3835_3836delTT; 4006delA; 4010del4; 4015delA; 4022insT; 3908dupA; 4040delA; 4048insCC; 4089ins4; 4203TAG->AA; 4218insT; Q2X (together with R3W); S4X; E7X; K14X; G27X; Q30X; Y38X; W57X(TAG); W57X(TGA); W79X; L88X(T- >A); L88X(T- >G); L101X; G103X; Y109X; L127X; L159X; E193X; Q207X; W216X; L218X; C225X; 717delG; Y247X; 825C>G; Q290X; Y304X; L320X; W356X; 1086T>A; 1114C>T; E379X; Q414X; S434X; E479X; G486X; E504X; G550X; L568X; 5230 S. State Road, Ann Arbor, MI Tel Fax progenity.com Page 2 of 8

3 Y569X; G576X; Q634X; S776X; Q781X; R785X; Q637X; E656X; E664X; G673X; W679X; Q685X; K688X; Q814X; E823X; E1418X; 360delT; 234delC; insT; 264_268delATATT ; Y913X; K946X; K978X; L1059X; W1063X; Q1071X; M1T; S1255P; G1349D; 435insA; 441delA; 451del8; 458delAT; 460delG; 489delC; 519delT; 525delT; 405_406dupAC; 541del4; 541delC; 546insCTA; 547insGA; 675del4; 1497delGG; 2406delCC; 2409delC; 2456delAC; 2512delG; 2522insC; 2556insAT; 2566insT; 2876delC; 3028delA; 3041delG; 3056delGA; 3732delA; E827X; K830X; E474X; W846X (2670TGG>TGA); Y849X; E51X; R104X; 733delG; 650_659delAGTTGTTACA ; 714delT; 874Ins TACA; 905delG; insA; 991del5; 1013delAA; 1058delC; 1112delT ; 1119delA; 1138insG; 1150delA; 1161insG; 1161delC; M1K; 1215delG; 1111dupA; 1283delA; 1289insTA; 1291delTT; T388X; 1309delG; 1227delT; 1366delG; K52X; E54X; E56X; C276X; R59X; S63X; K64X; K65X; K68X; C76X; W79X; R80X; Y84X; G85X; Y89X; L90X; 1086T>G; L219X; E267X; 2044delA; E286X; S341X; R1128X; K413X; C831X; L571X; Y577X; Y577X; L581X; L581X; E588X; E838X; 1199delG; L320X; 1323insA; L570X; L570X; 1813insC; L571X; K857X; L859X; L859X; W865X; E883X; G885X; G>C; 1824delA; 2694delT; 2055del9->A; A561E; G>C; 3100insA; E115X; E116X; L127X; C128X; G149X; Y161X; K162X; K163X; K174X; G178X; Q179X; K190X; G194X; L197X; L206X; E217X; L219X; G226X; Q237X; R242X; K246X; Y247X; K254X; E257X; R258X; S263X; S263X; E264X; Q270X; K273X; L288X; L288X; R289X; E292X; K294X; K298X; Y301X; R303X; S308X; S313X; K329X; C343X; W356X; Q359X; W1098X(TAG); W1098X(TGA); R1102X; K1177X; Y1182X; Q1186X; 1645_1648delAGTG; Y852X; L867X; 4272C>A; 211delG; 237insA; 241delAT; 284delA; 295ins8 ; 300delA; 306delTAGA; 306insA; 198_202delTCCTA; 347delC; insT; 1784delG; 1787delA; 1660_1661insA; 1802delC; 1806delA; 1833delT; 1845delAG/1846delGA; 1870delG; 1874insT; 2051delTT; 2113delA; 2116delCTAA; 2141insA; 2176insC; 2185insC; 2603delT; 2634delT; 2634insT; 2640delT; 2554dupT; 2566_2567insT; 2721del11; 2723delTT; 2732insA; 2734G- >AT; 2747delC; 2766del8 ; 2686_2687insT; 2705delG; 2896insAG; 2907delTT; 2909delT; 2789delG; 2803_2813delCTACCACTGGT; 2942insT; D110N; D110Y; G480C; Q493delCA; Q493P; Q493R; I506T; 5230 S. State Road, Ann Arbor, MI Tel Fax progenity.com Page 3 of 8

4 1898+5G->T; D614G; R1162L; 3667del4; I1234V; S1235R; Q1238X; A->G; D1270N; N1303I; 710_711+ 5del7; G622D; 2043delG; del13insAGAAA; 2108delA; R668C; F1052V; G1069R; R1070W; R1070Q; H139L; H139R; I148T; L227R; 936delTA; R347L; Q359K; T360K; S364P; 1288insTA; C524X; Q525X; L558S; Y569H; P574H; G576A; D579G; V754M; insA; 2869insG; S977F; L997F; 3130delA; I1027T; 2183delAA; 405+3A>C; G85V; 3765A>G; R31C; R31L; 296(+2)T>A; 296(+2)T>C; 296(+2)T>G; R74W; R75Q; 708delT Dihydrolipoamide dehydrogenase deficiency DLD p.g229c, p.y35x Ashkenazi Jewish 1 in in 2,121 Familial dysautonomia IKBKAP IVS20(+6)T>C, p.r696p Ashkenazi Jewish 1 in 31 1 in 3,001 Familial hyperinsulinism, ABCC8-related ABCC8 c g>a, delf1388 Ashkenazi Jewish 1 in 52 1 in % 1 in 1,701 1 in 184 Fanconi anemia, type C FANCC c.322delg, IVS4(+4)A>T, p.r548x Ashkenazi Jewish 1 in 89 1 in 8,801 1 in in 878 Fragile X syndrome* FMR1 CGG repeat analysis 1 in Gaucher disease GBA IVS2+1G>A, p.d409h, p.d409v, p.l444p, p.l47x, p.n370s, p.r496h, p.v394l Ashkenazi Jewish 1 in 18 1 in % 1 in in 279 Glycogen storage disease, type la G6PC p.q347x, p.r83c Ashkenazi Jewish 1 in 71 1 in 7,001 1 in % 1 in 321 Hemoglobinopathy evaluation N/A N/A Hemoglobinopathy, Hb C HBB 19G>A African American 1 in 15 1 in 46 1 in 68 1 in 1,401 1 in 4,501 1 in 6,701 Indian 1 in in in 11,801 1 in 16,901 1 in 25,401 Southeast 1 in in in in 29,101 1 in 66,101 1 in 79,001 1 in 49,901 Hemoglobinopathy, Hb D HBB 364G>C African American 1 in 15 1 in 46 1 in 68 1 in 1,401 1 in 4,501 1 in 6,701 1 in in 11,801 1 in 16, S. State Road, Ann Arbor, MI Tel Fax progenity.com Page 4 of 8

5 Indian 1 in in in in 25,401 1 in 29,101 1 in 66,101 Southeast 1 in in 79,001 1 in 49,901 Hemoglobinopathy, Hb E HBB 79G>A African American 1 in 15 1 in 46 1 in 1,401 1 in 4,501 1 in 68 1 in in 6,701 1 in 11,801 1 in 16,901 Indian 1 in in in in 25,401 1 in 29,101 1 in 66,101 Southeast 1 in in 79,001 1 in 49,901 Hemoglobinopathy, Hb O HBB 364G>A African American 1 in 15 1 in 46 1 in 1,401 1 in 4,501 1 in 68 1 in in 6,701 1 in 11,801 1 in 16,901 Indian 1 in in in in 25,401 1 in 29,101 1 in 66,101 Southeast 1 in in 79,001 1 in 49,901 Hemoglobinopathy, Sickle cell anemia (HbS) HBB 20A>T African American 1 in 14 1 in in 1,301 1 in 17,501 1 in in in in 18,201 1 in 35,901 1 in 62,401 Indian 1 in in in 1,336 1 in 72,401 1 in 77,401 1 in 133,501 Southeast 1 in 4,004 1 in 25 1 in 400,301 1 in 2,401 Joubert syndrome 2 TMEM216 p.r12l Ashkenazi Jewish 1 in 92 1 in 1,821 Maple syrup urine disease, type IA BCKDHA p.y438n Ashkenazi Jewish Mennonite 1 in 81 1 in 10 1 in in 8,001 1 in in S. State Road, Ann Arbor, MI Tel Fax progenity.com Page 5 of 8

6 Maple syrup urine disease, type IB BCKDHB p.e372x, p.g278s, p.r183p Ashkenazi Jewish 1 in 81 1 in in 8,001 1 in 267 Mucolipidosis type IV MCOLN1 del6.4kb, IVS3-2A>G Ashkenazi Jewish 1 in in 2,521 Nemaline myopathy 2 NEB p.r2478_d2512del Ashkenazi Jewish 1 in in 10,701 Niemann-Pick disease, type A and B SMPD1 delr608, fs330, p.l302p, p.r496l Ashkenazi Jewish 1 in 90 1 in % 20% 1 in 2,968 1 in 312 Northern African 1 in % 1 in 1,916 Spinal muscular atrophy SMN1 SMN2 Copy number analysis Two Copies SMN1 Three copies SMN1 Ashkenazi Jewish 1 in 35 1 in 41 1 in 53 93% 1 in in 3,500 1 in in 4,000 1 in in 5,000 African American 1 in 66 1 in in 50 71% 91% -- 1 in in 3,000 1 in 1,061 1 in 11, Tay-Sachs disease (DNA) HEXA 1278+TATC, IVS12+1G>C, IVS7+1G>A, IVS9+1G>A, p.g269s, p.r178h, p.r247w, p.r249w, del7.6kb Ashkenazi Jewish French Canadian/Cajun 1 in % 82% 59% 1 in in in 730 Tay-Sachs disease (hexosaminidase A) N/A N/A Ashkenazi Jewish French Canadian/Cajun 1 in 31 98% 98% 1 in 1,493 1 in 1, % 1 in 14,948 Usher syndrome, type IF PCDH15 p.r245x Ashkenazi Jewish 1 in in % 1 in in 439 Usher syndrome, type III CLRN1 528T>G, p.n48k Ashkenazi Jewish 1 in in 2,381 Walker-Warburg syndrome FKTN p.f390x Ashkenazi Jewish 1 in in 2,981 *X-linked disorder; carrier frequency and residual risk provided apply to females only. Additional variants evaluated as of April 1, S. State Road, Ann Arbor, MI Tel Fax progenity.com Page 6 of 8

7 Preparent Standard Panel Test References 1. Alter BP, Kupfer G. Fanconi Anemia. GeneReviews. Last updated February 7, Available at: 2. American College of Medical Genetics and Genomics (ACMG) Practice Guidelines. screening in individuals of Ashkenazi Jewish descent. Genet Med. 2008;10(1): American College of Obstetricians and Gynecologists (ACOG) Committee Opinion Number 318. Screening for Tay-Sachs Disease. Obstet Gyn Oct;106(4): American College of Obstetricians and Gynecologists (ACOG) Committee Opinion Number 442. Preconception and Prenatal Screening for Genetic Diseases in Individuals of Eastern European Jewish Descent. Obstet Gyn Oct;114(4): American College of Obstetrics and Gynecology Committee Opinion Number 486. Update on Screening for Cystic Fibrosis. Obstet Gyn Apr;117(4): American College of Obstetrics and Gynecology Committee Opinion Number 78. Hemoglobinopathies in pregnancy. Obstet Gyn Jan;109(1): Anderson SL, Ekstein J, Donnelly MC, et al. Nemaline myopathy in the Ashkenazi Jewish population is caused by a deletion in the nebulin gene. Hum Genet Aug;115(3): [PMID: ] 8. Axelrod FB, Gold-Von Simson G. Familial dysautonomia. Orphanet. Last updated November Available at: http// php?lng=en&data_id= Bali DS, Chen Y, Goldstein JL. Glycogen Storage Disease Type 1. GeneReviews. Last updated September 19, Available at: Bender MA, Seibel GD. Sickle Cell Disease. GeneReviews. Last updated October 23, Available at: Blanchet C, Hamel C. Usher Syndrome. Orphanet. Last updated February Available at Brancati F, Dallapiccola B, Valente EM. Orphanet. Joubert syndrome. Last updated July Available at: http// Disease_Search.php?lng=EN&data_id= Caillaud C. Mucolipidosis Type 4. Orphanet. Last updated June Available at: http// 14. Cao A, Galanello R, Origa R. Beta-Thalassemia. GeneReviews. Last updated May 14, Available at: Chang W, Winder TL, LeDuc CA, et al. Founder fukutin mutation causes Walker-Warburg syndrome in four Ashkenazi Jewish families. Prenat Diagn Jun;29(6): Driscoll, DA, Sehdev HM, Marchiano DA. Prenatal Screening for Genetic Conditions. Neoreviews. 2004;5:e Edvardson S, Shaag A, Zenvirt S, et al. Joubert syndrome 2 (JBTS2) in Ashkenazi Jews is associated with a TMEM216 mutation. Am J Hum Genet Jan;86(1):93-7. [PMID: ] 18. Ekstein J, Rubin BY, Anderson SL, et al. Mutation frequencies for glycogen storage disease Ia in the Ashkenazi Jewish population. Am J Med Genet Aug 30;129A(2): Elpeleg ON, Shaag A. The spectrum of mutations of the aspartoacylase gene in Canavan disease in non-jewish patients. J Inherit Metab Dis Jun;22(4): [PMID: ] 20. Genetics Home Reference. Gaucher Disease. Last updated September Available at: http// in condition in gaucher-disease. 21. Genetics Home Reference. Glycogen Storage Disease Type 1A. Last updated September Available at: http// in condition in glycogen-storage-disease-type-i. 22. Glaser B, Blech I, Krakinovsky Y, et al. ABCC8 mutation allele frequency in the Ashkenazi Jewish population and risk of focal hyperinsulinemic hypoglycemia. Genet Med Oct;13(10): [PMID: ] 23. Glaser B. Familial Hyperinsulinism. GeneReviews. Last updated January 24, Available at: Hechtman P, Kaplan F, Bayleran J, et al. More than one mutant allele causes infantile Tay-Sachs disease in French-Canadians. Am J Hum Genet Nov;47(5): [PMID: ] 25. Hendrickson BC, Donohoe C, Akmaev VR, et al. Differences in SMN1 allele frequencies among ethnic groups within North America. J Med Genet Sept;46(9): [PMID ] 26. Jalas C, Anderson SL, Laufer T, Martimucci K, Bulanov A, Xie X, Ekstein J, Rubin BY. A founder mutation in the MPL gene causes congenital amegakaryocytic thrombocytopenia (CAMT) in the Ashkenazi Jewish population. Blood Cells Mol Dis Jun 15;47(1): [PMID: ] 27. Kaback MM, Desnick RJ. Hexosaminidase A Deficiency. GeneReviews. Last updated August 11, Available at: Kaul R, Gao GP, Matalon R, et al. Identification and expression of eight novel mutations among non-jewish patients with Canavan disease. Am J Hum Genet Jul;59(1): [PMID: ] 29. Keat BJB, Lentz J. Usher Syndrome Type I. GeneReviews. Last updated June 20, Available at: Lal A, Goldrich ML, Haines DA, Azimi M, Singer ST, Vichinsky EP. Heterogeneity of hemoglobin H disease in childhood. N Engl J Med Feb 24;364(8): Lorey F, Arnopp J, et al. Distribution of hemoglobinopathy variants by ethnicity in a multiethnic state. Genetic Epidemiol. 1996;13: S. State Road, Ann Arbor, MI Tel Fax progenity.com Page 7 of 8

8 32. Manzini MC, Gleason D, Chang BS, et al. Ethnically diverse causes of Walker-Warburg Syndrome (WWS): FCMD mutations are a more common cause of WWS outside of the Middle East. Hum Mutat. 2008;29(11): Matalon K, Matalon R. Canavan disease. Orphanet. Last updated December Available at: http// 34. McGovern MM, Schuchman EH. Acid Spingomyelinase Deficiency. GeneReviews. Last updated June 25, Available at: North KN, Ryan MM. Nemaline Myopathy. GeneReviews. Last updated September 18, Available at: Origa R, Moi P, Galanello R, Cao A. Alpha-Thalassemia. GeneReviews. Last updated December 29, Available at: Orphanet. Gaucher Disease. Last updated February Available at: http// 38. Orphanet. Walker-Warburg Syndrome. Last updated December Available at: Parisi M, Glass I. Joubert Syndrome and Related Disorders. GeneReviews. Last updated April 11, Available at: Pastores GM, Hughes DA. Gaucher Disease. GeneReviews. Last updated September 19, Available at: Population Surveys, Beta-Thalassemia Alleles. Available at: Accessed January 14, Quinonez SC, Thoene JG. Dihydrolipoamide Dehydrogenase Deficiency. GeneReviews. Last updated July 17,2014. Available at: Sanz M, German J. Bloom s Syndrome. GeneReviews. Last updated March 28, Available at: Schrijver I, Külm M, Gardner PI, Pergament EP, Fiddler MB. Comprehensive arrayed primer extension array for the detection of 59 sequence variants in 15 conditions prevalent among the (Ashkenazi) Jewish population. J Mol Diagn Apr;9(2): [PMID ] 45. Schuchman EH. The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease. J Inherit Metab Dis. 2007;30: Scott SA, Edelmann L, Liu L, Luo M, Desnick RJ, Kornerich R. Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. Hum Mutat Nov;31(11): [PMID ] 47. Shaag A, Anikster Y, Christensen E, et al. The molecular basis of canavan (aspartoacylase deficiency) disease in European non-jewish patients. Am J Hum Genet Sep;57(3): [PMID: ] 48. Shohat M, Halpern G. Familial Dysautonomia. GeneReviews. Last updated June 1, Available at: Sistermans EA, de Coo RF, van Beerendonk HM, et al. Mutation detection in the aspartoacylase gene in 17 patients with Canavan disease: four new mutations in the non-jewish population. Eur J Hum Genet Jul;8(7): [PMID: ] 50. Strauss KA, Puffenberger EG, Morton DH. Maple Syrup Urine Disease. GeneReviews. Last updated May 9, Available at: Vanier MT, Ferlinz K, Rousson R, et al. Deletion of arginine (608) in acid sphingomyelinase is the prevalent mutation among Niemann-Pick disease type B patients from northern Africa. Hum Genet Oct;92(4): Vives-Corrons JL. Congenital amegakaryocytic thrombocytopenia. Orphanet. Last updated August Available at: http// php?lng=en&data_id=3053. Progenity is a CLIA-certified clinical laboratory and is accredited by the College of American Pathologists (CAP). The information contained in this document is provided as an educational service for healthcare providers and their patients Progenity, Inc. All rights reserved. Progenity is a registered service mark of Progenity, Inc. Preparent is a trademark of Progenity, Inc. CO REV S. State Road, Ann Arbor, MI Tel Fax progenity.com Page 8 of 8

PATIENT EDUCATION. carrier screening INFORMATION

PATIENT EDUCATION. carrier screening INFORMATION PATIENT EDUCATION carrier screening INFORMATION carrier screening AT A GLANCE Why is carrier screening recommended? Carrier screening is one of many tests that can help provide information to you and your

More information

QHerit Expanded Carrier Screen

QHerit Expanded Carrier Screen QHerit Expanded Carrier Screen Test Code: 94372 (X) Specimen Requirements: Preferred: 6 ml (4 ml minimum) room-temperature whole blood: 1.5 ml (1 ml minimum) in each of 4 lavender-top (EDTA) or yellow-top

More information

A Lawyer s Perspective on Genetic Screening Performed by Cryobanks

A Lawyer s Perspective on Genetic Screening Performed by Cryobanks A Lawyer s Perspective on Genetic Screening Performed by Cryobanks As a lawyer practicing in the area of sperm bank litigation, I have, unfortunately, represented too many couples that conceived a child

More information

Exomes and Beyond Addressing the Genome with OneSeq. Madhuri Hegde, PhD, FACMG Emory University Emory Genetics Laboratory Atlanta, GA

Exomes and Beyond Addressing the Genome with OneSeq. Madhuri Hegde, PhD, FACMG Emory University Emory Genetics Laboratory Atlanta, GA Exomes and Beyond Addressing the Genome with OneSeq Madhuri Hegde, PhD, FACMG Emory University Emory Genetics Laboratory Atlanta, GA Technologies to Detect Various Types of Mutations RESOLUTION Targeted

More information

Expanded Carrier Screening: What s Best?

Expanded Carrier Screening: What s Best? Expanded Carrier Screening: What s Best? James D Goldberg, MD September 17, 2017 Disclosures James D. Goldberg, M.D. Chief Medical Officer, Counsyl 3 Learning Objectives Guidelines Data Design Practice

More information

23andMe Personal Genome Service (PGS) Carrier Status Tests Package Insert

23andMe Personal Genome Service (PGS) Carrier Status Tests Package Insert Table of contents Intended Use Important warnings and limitations Test performance User studies Specific test information 23andMe Personal Genome Service (PGS) Carrier Status Tests Package Insert For in-vitro

More information

EVOLVE CARRIER GENETIC SCREENS. Better health for generations to come! Be Proactive. SCREEN TODAY. PROTECT TOMORROW.

EVOLVE CARRIER GENETIC SCREENS. Better health for generations to come! Be Proactive. SCREEN TODAY. PROTECT TOMORROW. EVOLVE CARRIER GENETIC SCREENS Better health for generations to come! Be Proactive. SCREEN TODAY. PROTECT TOMORROW. PROTECT THE HEALTH OF YOUR FUTURE CHILDREN BY KNOWING YOUR GENETIC RISKS, TODAY! Carrier

More information

BROADENING YOUR PATIENT S OPTIONS FOR GENETIC CARRIER SCREENING.

BROADENING YOUR PATIENT S OPTIONS FOR GENETIC CARRIER SCREENING. BROADENING YOUR PATIENT S OPTIONS FOR GENETIC CARRIER SCREENING. The Inheritest SM Carrier Screen provides relevant genetic screening for many inherited diseases found throughout the pan-ethnic US population.

More information

23andMe Personal Genome Service (PGS) Carrier Status Tests Package Insert

23andMe Personal Genome Service (PGS) Carrier Status Tests Package Insert Table of contents Intended Use Important warnings and limitations Test performance User studies Specific test information 23andMe Personal Genome Service (PGS) Carrier Status Tests Package Insert For in-vitro

More information

Should Universal Carrier Screening be Universal?

Should Universal Carrier Screening be Universal? Should Universal Carrier Screening be Universal? Disclosures Research funding from Natera Mary E Norton MD University of California, San Francisco Antepartum and Intrapartum Management June 15, 2017 Burden

More information

Cystic fibrosis carrier screening in a North American population

Cystic fibrosis carrier screening in a North American population American College of Medical Genetics and Genomics Original Research Article Cystic fibrosis carrier screening in a North American population Val V. Zvereff, MD,PhD 1, Hawazin Faruki, DrPh 1, Marcia Edwards,

More information

NutraHacker. Carrier and Drug Response Report for Customer: b2b0b618-db91-447c-9470-ff7b79ae147d. Instructions:

NutraHacker. Carrier and Drug Response Report for Customer: b2b0b618-db91-447c-9470-ff7b79ae147d. Instructions: NutraHacker Carrier and Drug Response Report for Customer: b2b0b618-db91-447c-9470-ff7b79ae147d Instructions: In this report, NutraHacker examines single nucleotide polymorphisms that reveal carrier status

More information

SUPPLEMENTARY INFORMATION. Rare independent mutations in renal salt handling genes contribute to blood pressure variation

SUPPLEMENTARY INFORMATION. Rare independent mutations in renal salt handling genes contribute to blood pressure variation SUPPLEMENTARY INFORMATION Rare independent mutations in renal salt handling genes contribute to blood pressure variation Weizhen Ji, Jia Nee Foo, Brian J. O Roak, Hongyu Zhao, Martin G. Larson, David B.

More information

Genetic Testing FOR DISEASES OF INCREASED FREQUENCY IN THE ASHKENAZI JEWISH POPULATION

Genetic Testing FOR DISEASES OF INCREASED FREQUENCY IN THE ASHKENAZI JEWISH POPULATION Carrier Screening and Diagnostic Testing for the Ashkenazi Jewish Population Genetic Testing FOR DISEASES OF INCREASED FREQUENCY IN THE ASHKENAZI JEWISH POPULATION Our Science. Your Care. An extensive

More information

Related Policies None

Related Policies None Medical Policy MP 2.04.107 BCBSA Ref. Policy: 2.04.107 Last Review: 04/30/2018 Effective Date: 04/30/0218 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational

More information

A Comprehensive Study of TP53 Mutations in Chronic Lymphocytic Leukemia: Analysis of 1,287 Diagnostic CLL Samples

A Comprehensive Study of TP53 Mutations in Chronic Lymphocytic Leukemia: Analysis of 1,287 Diagnostic CLL Samples A Comprehensive Study of TP53 Mutations in Chronic Lymphocytic Leukemia: Analysis of 1,287 Diagnostic CLL Samples Sona Pekova, MD., PhD. Chambon Ltd., Laboratory for molecular diagnostics, Prague, Czech

More information

Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis

Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis Clinical Appropriateness Guidelines Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis EFFECTIVE OCTOBER 14, 2017 Appropriate.Safe.Affordable 2017 AIM Specialty Health 2068-1017

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Carrier Screening for Genetic Disease File Name: Origination: Last CAP Review: Next CAP Review: Last Review: carrier_screening_for_genetic_disease 12/2013 7/2017 7/2018 7/2017

More information

UW359 Ovary 3c 3 Serous Recurrent 68 BRCA1 816delGT BRCA1 del exon 1-2. UW417 Ovary 3c 3 Serous Primary 38 BRCA1 1675delA

UW359 Ovary 3c 3 Serous Recurrent 68 BRCA1 816delGT BRCA1 del exon 1-2. UW417 Ovary 3c 3 Serous Primary 38 BRCA1 1675delA Supplementary Table 1. Cases with deleterious germline mutations, somatic HR mutations, and somatic PTEN mutations. ID Site Stage Grade Histology Tumor Age Germline mutation(s) a Somatic HR mutation(s)

More information

BE PROACTIVE. SCREEN TODAY. PROTECT TOMORROW.

BE PROACTIVE. SCREEN TODAY. PROTECT TOMORROW. BE PROACTIVE. SCREEN TODAY. PROTECT TOMORROW. THE LEADER IN FERTILITY & REPRODUCTIVE GENETIC SCREENING EvolveGene was founded by world leaders in preventive and personalized health care, with over 25 years

More information

Results Recipient Ordering Healthcare Professional Male Details Female Details

Results Recipient Ordering Healthcare Professional Male Details Female Details Results Recipient Ordering Healthcare Professional Male Details Details Report Date /2010 Attn: Jessica Jacobson, MD Counsyl, Inc. 2200 Bridge Parkway, Suite 103 Redwood City, CA 94065 Phone: 1-888-COUNSYL

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Wells JM, Farris RF, Gosdin TA, et al. Pulmonary

More information

An Effective Model to Communicate Complex Genetic Information to Families and Health Care Providers

An Effective Model to Communicate Complex Genetic Information to Families and Health Care Providers An Effective Model to Communicate Complex Genetic Information to Families and Health Care Providers Theresa Steckel, RN, BSN Newborn Screening Quality Assurance and Education Coordinator Oklahoma State

More information

Donor xytex.com

Donor xytex.com Donor 5472 Information displayed in this profile is provided by the donor. Blank fields are intentional and indicate that the information is not available. xytex.com info@xytex.com 706-733-0130 General

More information

GENETIC TESTING AND COUNSELING FOR HERITABLE DISORDERS

GENETIC TESTING AND COUNSELING FOR HERITABLE DISORDERS Status Active Medical and Behavioral Health Policy Section: Laboratory Policy Number: VI-09 Effective Date: 03/17/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members

More information

Intron 1 IVS1+5G>T --- Greenberg et al, Exon II del2 Tsai et al, 2017 K42R 125A>G Spector et al, unpublished

Intron 1 IVS1+5G>T --- Greenberg et al, Exon II del2 Tsai et al, 2017 K42R 125A>G Spector et al, unpublished Exon I M1V 1A>G Kolker et al, 2007 --- 11delG Spector & Sharer, unpublished S25L 74C>T Spector et al, unpublished --- 89/90 delc Mushimoto et al, 2011 88-91del4+IVS1 gtca Spector et al, unpublished Intron

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY Policy Name: Policy Number: Approved By: CLINICAL MEDICAL POLICY Genetic Testing for Cystic Fibrosis MP-006-MD-DE Provider Notice Date: 11/1/2016 Original Effective Date: 12/1/2016 Annual Approval Date:

More information

Carrier Screening for Genetic Diseases

Carrier Screening for Genetic Diseases Medical Policy Manual Genetic Testing, Policy No. 81 Carrier Screening for Genetic Diseases Next Review: September 2018 Last Review: December 2017 Effective: January 1, 2018 IMPORTANT REMINDER Medical

More information

QUESTION. Personal Behavior History. Donor Genetic History. Donor Medical History. Family Medical History PERSONAL BEHAVIOR HISTORY. Never N/A.

QUESTION. Personal Behavior History. Donor Genetic History. Donor Medical History. Family Medical History PERSONAL BEHAVIOR HISTORY. Never N/A. Donor 4576 Medical Profile S Personal Behavior History Donor Genetic History Donor Medical History Family Medical History PERSONAL BEHAVIOR HISTORY Current alcohol use: If yes, oz./week and type of alcohol:

More information

Foresight Carrier Screen

Foresight Carrier Screen 4915 25th Ave NE, Suite 204W Seattle, WA 98105 Phone: (206) 588-1484 Fax: (206) 466-4696 Sample Type: EDTA Blood Date of Collection: 09/20/2017 Date Received: 09/22/2017 Date Tested: 09/27/2017 Indication:

More information

IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT MARCH 13, 2012

IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT MARCH 13, 2012 IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT201208 MARCH 13, 2012 Updates to the 2012 Healthcare Common Coding System This bulletin updates information published by the Indiana Health Coverage Programs

More information

Exon I M1V 1A>G Kolker et al, delG Spector & Sharer, unpublished /90 delc Mushimoto et al, 2011

Exon I M1V 1A>G Kolker et al, delG Spector & Sharer, unpublished /90 delc Mushimoto et al, 2011 Exon I M1V 1A>G Kolker et al, 2007 --- 11delG Spector & Sharer, unpublished 2006 --- 89/90 delc Mushimoto et al, 2011 Intron 1 IVS1+5G>T --- Greenberg et al, 1995 Exon II --- 109-110delCA Tsai et al, 2017

More information

Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis

Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis Clinical Appropriateness Guidelines Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis EFFECTIVE MARCH 31, 2019 Appropriate.Safe.Affordable 2019 AIM Specialty Health 2068-0319 Table

More information

JOHN DOE JANE DOE. Reproductive Risk Summary. Counsyl Test Results Summary

JOHN DOE JANE DOE. Reproductive Risk Summary. Counsyl Test Results Summary Results Recipient University Medical Center 827 Attn: Dr. Paul Smith 123 Main Street Houston, TX 10231 Phone: (800) 555-1212 Fax: (800) 555-1212 NPI: 7834324983 Report Date: 09/09/2013 Female Ethnicity:

More information

Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis

Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis Federico Goodsaid Vice President Strategic Regulatory Intelligence Vertex Pharmaceuticals Is there

More information

MEDICAL POLICY SUBJECT: PRENATAL GENETIC TESTING. POLICY NUMBER: CATEGORY: Laboratory Test

MEDICAL POLICY SUBJECT: PRENATAL GENETIC TESTING. POLICY NUMBER: CATEGORY: Laboratory Test MEDICAL POLICY SUBJECT: PRENATAL GENETIC TESTING PAGE: 1 OF: 9 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including

More information

Medical Policy. Description/Scope. Position Statement

Medical Policy. Description/Scope. Position Statement Subject: Document #: Current Effective Date: 03/29/2017 Status: Reviewed Last Review Date: 02/02/2017 Description/Scope This document addresses preconceptional or prenatal genetic testing on a parent or

More information

Genetic Carrier Screening

Genetic Carrier Screening Genetic Carrier Screening Test Indications Carrier screening is a significant testing tool for inherited genetic conditions of prenatal care. The purpose of carrier screening is to identify couples at-risk

More information

Genomics in Women s Health: Changing the Diagnostic and Therapeutic Paradigm

Genomics in Women s Health: Changing the Diagnostic and Therapeutic Paradigm Genomics in Women s Health: Changing the Diagnostic and Therapeutic Paradigm Lee P. Shulman MD The Anna Ross Lapham Professor in Obstetrics and Gynecology Feinberg School of Medicine of Northwestern University

More information

Supplementary Table e1. Clinical and genetic data on the 37 participants from the WUSM

Supplementary Table e1. Clinical and genetic data on the 37 participants from the WUSM Supplementary Data Supplementary Table e1. Clinical and genetic data on the 37 participants from the WUSM cohort. Supplementary Table e2. Specificity, sensitivity and unadjusted ORs for glioma in participants

More information

Fabry Disease X-linked genetic, multi-organ disorder. Fabry disease screening program in Hypertrophic p Cardiomyopathy: preliminary results.

Fabry Disease X-linked genetic, multi-organ disorder. Fabry disease screening program in Hypertrophic p Cardiomyopathy: preliminary results. Fabry Disease X-linked genetic, multi-organ disorder Fabry disease screening program in Hypertrophic p Cardiomyopathy: y preliminary results. Globotriaosylceramide, GL3 Brain -galactosidase A Eyes Lactosylceramide

More information

Supplementary Figure 1

Supplementary Figure 1 Count Count Supplementary Figure 1 Coverage per amplicon for error-corrected sequencing experiments. Errorcorrected consensus sequence (ECCS) coverage was calculated for each of the 568 amplicons in the

More information

Deliverable 2.1 List of relevant genetic variants for pre-emptive PGx testing

Deliverable 2.1 List of relevant genetic variants for pre-emptive PGx testing GA N 668353 H2020 Research and Innovation Deliverable 2.1 List of relevant genetic variants for pre-emptive PGx testing WP N and Title: WP2 - Towards shared European Guidelines for PGx Lead beneficiary:

More information

23andMe Reports GENETIC HEALTH RISK REPORTS. Increased risk for breast and ovarian cancer. function

23andMe Reports GENETIC HEALTH RISK REPORTS. Increased risk for breast and ovarian cancer. function 1 23andMe Reports GENETIC HEALTH RISK REPORTS BRCA1/BRCA2 Late-Onset Alzheimer's Disease Parkinson's Disease Age-Related Macular Degeneration Alpha-1 Antitrypsin Deficiency Celiac Disease G6PD Deficiency

More information

To test the possible source of the HBV infection outside the study family, we searched the Genbank

To test the possible source of the HBV infection outside the study family, we searched the Genbank Supplementary Discussion The source of hepatitis B virus infection To test the possible source of the HBV infection outside the study family, we searched the Genbank and HBV Database (http://hbvdb.ibcp.fr),

More information

Supplemental Table 1. The list of variants with their respective scores for each variant classifier Gene DNA Protein Align-GVGD Polyphen-2 CADD MAPP

Supplemental Table 1. The list of variants with their respective scores for each variant classifier Gene DNA Protein Align-GVGD Polyphen-2 CADD MAPP Supplemental Table 1. The list of variants with their respective scores for each variant classifier Gene DNA Protein Align-GVGD Polyphen-2 CADD MAPP Frequency Domain Mammals a 3 S/P b Mammals a 3 S/P b

More information

Kalydeco. Kalydeco (ivacaftor) Description

Kalydeco. Kalydeco (ivacaftor) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.03 Subject: Kalydeco Page: 1 of 6 Last Review Date: November 30, 2018 Kalydeco Description Kalydeco

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY CLINICAL MEDICAL POLICY Policy Name: Genetic Testing for Cystic Fibrosis Policy Number: MP-006-MD-DE Approved By: Medical Management Provider Notice Date: 04/15/2018; 11/01/2016 Issue Date: 05/15/2018

More information

Clinical Policy Title: Genetic testing for maple syrup urine disease

Clinical Policy Title: Genetic testing for maple syrup urine disease Clinical Policy Title: Genetic testing for maple syrup urine disease Clinical Policy Number: 02.01.27 Effective Date: June 1, 2018 Initial Review Date: April 10, 2018 Most Recent Review Date: May 1, 2018

More information

Support. Overview. Auditory Dys-synchrony. Auditory Brainstem Response. Potential Causes

Support. Overview. Auditory Dys-synchrony. Auditory Brainstem Response. Potential Causes Potential Role of Genetic Testing in Auditory Neuropathy/Dys-synchrony Christina Runge-Samuelson, Ph.D., CCC-A Associate Professor Co-Director, Koss Cochlear Implant Program Department of tolaryngology

More information

Genetic Carrier Testing Cystic Fibrosis (CF) Spinal Muscular Atrophy (SMA) Fragile X Syndrome

Genetic Carrier Testing Cystic Fibrosis (CF) Spinal Muscular Atrophy (SMA) Fragile X Syndrome Genetic Carrier Testing Cystic Fibrosis (CF) Spinal Muscular Atrophy (SMA) Fragile X Syndrome It s about knowing. Prenatal testing is not about telling you what s wrong, it s knowing that everything is

More information

Centers for Medicare and Medicaid Services

Centers for Medicare and Medicaid Services Centers for Medicare and Medicaid Services Clinical Laboratory Fee Schedule Annual Laboratory Public Meeting June 25, 2018 Anthony Sireci, MD, Msc Association for Molecular Pathology Outline Germline Procedures

More information

Expanded carrier screening in an infertile population: how often is clinical decision making affected?

Expanded carrier screening in an infertile population: how often is clinical decision making affected? American College of Medical Genetics and Genomics Original Research Article Expanded carrier screening in an infertile population: how often is clinical decision making affected? Jason M. Franasiak, MD

More information

Foresight Carrier Screen

Foresight Carrier Screen 4915 25th Ave NE, Suite 204W Seattle, WA 98105 Phone: (206) 588-1484 Fax: (206) 466-4696 Sample Type: EDTA Blood Date of Collection: 08/17/2017 Date Received: 08/18/2017 Date Tested: 08/24/2017 Indication:

More information

CMS will not implement the new tier codes for Medicare/Medicaid claims for calendar year 2012.

CMS will not implement the new tier codes for Medicare/Medicaid claims for calendar year 2012. January 1, 2012 Re: 2012 AMA CPT Code Changes Dear Valued Client: The American Medical Association (AMA) has made Current Procedural Terminology (CPT) code changes to the 2012 edition of the CPT coding

More information

CHRONIC MYELOGENOUS LEUKEMIA

CHRONIC MYELOGENOUS LEUKEMIA CHRONIC MYELOGENOUS LEUKEMIA SHUFFLING THE GENETIC DECK IN CML 9 9 (q+) 22 Ph (22q-) bcr bcr-abl abl Fusion protein causes cancer GLEEVEC AND BCR-ABL FUSION PROTEIN GENETIC MEDICINE A. Genetic diseases

More information

TEST INFORMATION Test: CarrierMap GEN (Genotyping) Panel: CarrierMap Expanded Diseases Tested: 311 Genes Tested: 299 Mutations Tested: 2647

TEST INFORMATION Test: CarrierMap GEN (Genotyping) Panel: CarrierMap Expanded Diseases Tested: 311 Genes Tested: 299 Mutations Tested: 2647 Ordering Practice Jane Smith John Smith Practice Code: 675 Miller MD 374 Broadway New York, NY 10000 Physician: Dr. Frank Miller Report Generated: 2016-02-03 DOB: 1973-02-19 Gender: Female Ethnicity: European

More information

ERCP findings in idiopathic pancreatitis: patients who are cystic fibrosis gene positive and negative

ERCP findings in idiopathic pancreatitis: patients who are cystic fibrosis gene positive and negative ORIGINAL ARTICLE ERCP findings in idiopathic pancreatitis: patients who are cystic fibrosis gene positive and negative Waleed M. Alazmi, MD, Evan L. Fogel, MD, Suzette Schmidt, RN, James L. Watkins, MD,

More information

Supplementary Figure 1. FACS analysis of cells infected with TY93/H5N1 GFP-627E,

Supplementary Figure 1. FACS analysis of cells infected with TY93/H5N1 GFP-627E, Supplementary Figure 1. FACS analysis of cells infected with TY93/H5N1 GFP-627E, TY93/H5N1 GFP-627K, or the TY93/H5N1 PB2(588-759) virus library. To establish our GFP- FACS screening platform, we compared

More information

Lab Prior Authorization

Lab Prior Authorization Lab Prior Authorization On July 22, 2015, BlueCross BlueShield of South Carolina announced that it will partner with Avalon Healthcare Solutions (Avalon) to administer a comprehensive suite of laboratory

More information

A Quick Guide to the. I507del. Mutation CFTR SCIENCE

A Quick Guide to the. I507del. Mutation CFTR SCIENCE A Quick Guide to the I507del Mutation CFTR SCIENCE 2016 Vertex Pharmaceuticals Incorporated VXR-HQ-02-00045a(1) 03/2016 Loss of CFTR activity is the underlying cause of cystic fibrosis (CF) 1 Spectrum

More information

The role of E148Q in FMF. Elon Pras Institute of Human Genetics Sheba Medical Center

The role of E148Q in FMF. Elon Pras Institute of Human Genetics Sheba Medical Center The role of E148Q in FMF Elon Pras Institute of Human Genetics Sheba Medical Center Familial Mediterranean Fever (FMF) Acute attacks of fever accompanied by: Peritonitis Pleuritis Arthritis Erysipelas

More information

BRCA Mutations and Outcome in Epithelial Ovarian Cancer: Experience in Ethnically Diverse Groups

BRCA Mutations and Outcome in Epithelial Ovarian Cancer: Experience in Ethnically Diverse Groups BRCA Mutations and Outcome in Epithelial Ovarian Cancer: Experience in Ethnically Diverse Groups Tamar Safra, MD, Barliz Waissengrin, MD, Lucia Borgato, MD, Moshe Leshno, MD, Elsa Reich, MD, Julia Smith,

More information

Donor xytex.com

Donor xytex.com Donor 5472 Information displayed in this profile is provided by the donor. Blank fields are intentional and indicate that the information is not available. xytex.com info@xytex.com 706-733-0130 General

More information

Genetic evaluation procedures at sperm banks in the United States

Genetic evaluation procedures at sperm banks in the United States Genetic evaluation procedures at sperm banks in the United States Lauren Isley, M.S., C.G.C. a and Pamela Callum, M.S., C.G.C. a,b a Assisted Reproductive Technology and Infertility Special Interest Group,

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Genetic Testing for Alpha Thalassemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_alpha_thalassemia 9/2013 7/2017 7/2018 7/2017 Description

More information

ORIGINAL INVESTIGATION. Carrier Screening for Cystic Fibrosis, Gaucher Disease, and Tay-Sachs Disease in the Ashkenazi Jewish Population

ORIGINAL INVESTIGATION. Carrier Screening for Cystic Fibrosis, Gaucher Disease, and Tay-Sachs Disease in the Ashkenazi Jewish Population ORIGINAL INVESTIGATION Carrier Screening for Cystic Fibrosis, Gaucher Disease, and Tay-Sachs Disease in the Ashkenazi Jewish Population The First 1000 Cases at New York University Medical Center, New York,

More information

Preparent Carrier Screen Global Panel Disorders

Preparent Carrier Screen Global Panel Disorders Preparent Screen Global Panel Disorders See next section for Global+ Panel disorders. Disorder Gene Variants Ethnicity 17-alpha-hydroxylase deficiency CYP17A1 1118A>T, 160_162delTTC 17-beta-hydroxysteroid

More information

helpful guide Carrier Testing for Common Genetic Diseases Hemoglobinopathies Cystic Fibrosis Spinal Muscular Atrophy Fragile X

helpful guide Carrier Testing for Common Genetic Diseases Hemoglobinopathies Cystic Fibrosis Spinal Muscular Atrophy Fragile X A helpful guide to Carrier Testing for Common Genetic Diseases Hemoglobinopathies Cystic Fibrosis Spinal Muscular Atrophy Fragile X Joseph Adashek, M.D., FACOG Paul T. Wilkes, M.D., FACOG Van R. Bohman,

More information

Sequencing in Newborn Screening Introduction and Background

Sequencing in Newborn Screening Introduction and Background Sequencing in Newborn Screening Introduction and Background Suzanne Cordovado, PhD Newborn Screening and Molecular Biology Branch Division of Laboratory Sciences Centers for Disease Control and Prevention

More information

Carrier Screening for Genetic Diseases. (204107) (Formerly Carrier Testing for Genetic Diseases)

Carrier Screening for Genetic Diseases. (204107) (Formerly Carrier Testing for Genetic Diseases) Protocol Carrier Screening for Genetic Diseases (204107) (Formerly Carrier Testing for Genetic Diseases) Medical Benefit Effective Date: 04/01/18 Next Review Date: 11/18 Preauthorization Yes Review Dates:

More information

Vertical Magnetic Separation of Circulating Tumor Cells and Somatic Genomic-Alteration Analysis in Lung Cancer Patients

Vertical Magnetic Separation of Circulating Tumor Cells and Somatic Genomic-Alteration Analysis in Lung Cancer Patients Vertical Magnetic Separation of Circulating Cells and Somatic Genomic-Alteration Analysis in Lung Cancer Patients Chang Eun Yoo 1,2#, Jong-Myeon Park 3#, Hui-Sung Moon 1,2, Je-Gun Joung 2, Dae-Soon Son

More information

Result Navigator. Positive Test Result: RAD51C. After a positive test result, there can be many questions about what to do next. Navigate Your Results

Result Navigator. Positive Test Result: RAD51C. After a positive test result, there can be many questions about what to do next. Navigate Your Results Result Navigator Positive Test Result: RAD51C Positive test results identify a change, or misspelling, of DNA that is known or predicted to cause an increased risk for cancer. DNA is the blueprint of life

More information

modified dye uptake assay including formazan test EC 90 not tested plaque reduction assay

modified dye uptake assay including formazan test EC 90 not tested plaque reduction assay Sauerbrei A, Bohn-Wippert K, Kaspar M, Krumbholz A, Karrasch M, Zell R. 2015. Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes

More information

ORIGINAL RESEARCH ARTICLE

ORIGINAL RESEARCH ARTICLE American College of Medical Genetics and Genomics Open An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23,453 individuals

More information

Variant annotation Extracted variants listed in dbsnp, OMIM, ClinVar, and HGMD 2434 variants

Variant annotation Extracted variants listed in dbsnp, OMIM, ClinVar, and HGMD 2434 variants Whole Genome Sequencing and Variant Calling Whole genome sequencing and variant calling of 128 healthy Ashkenazi Jews carried out by Complete Genomics. Merged 128 genomes using CGA tools, obtained 273250

More information

GENETIC SCREENING. Prof Dr Karen Sermon, MD, PhD LEARNING OBJECTIVES DISCLOSURE

GENETIC SCREENING. Prof Dr Karen Sermon, MD, PhD LEARNING OBJECTIVES DISCLOSURE GENETIC SCREENING Prof Dr Karen Sermon, MD, PhD LEARNING OBJECTIVES At the conclusion of this presentation, participants should be able to answer the following questions: What is (genetic) screening? Why

More information

THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF)

THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210. Vertex and the Vertex triangle logo are registered trademarks for Vertex

More information

CPTR title slide. A Standardized System for Grading Mutations in Mycobacterium tuberculosis for Association with Drug Resistance

CPTR title slide. A Standardized System for Grading Mutations in Mycobacterium tuberculosis for Association with Drug Resistance CPTR title slide A Standardized System for Grading Mutations in Mycobacterium tuberculosis for Association with Drug Resistance PAOLO MIOTTO CPTR 2017 Workshop, March 20 23 The Need A lack of user-friendly

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Cystic Fibrosis Transmembrane Page 1 of 11 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Prime Therapeutics

More information

article May/June 2001 Vol. 3 No. 3

article May/June 2001 Vol. 3 No. 3 article May/June 2001 Vol. 3 No. 3 Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded, pan-ethnic mutation panel Ruth A. Heim, PhD, Elaine A. Sugarman,

More information

FAMILY PLANNING DOESN T HAVE TO BE ONE OF THEM

FAMILY PLANNING DOESN T HAVE TO BE ONE OF THEM THE ESSENTIAL PANEL There are many unknowns in life. FAMILY PLANNING DOESN T HAVE TO BE ONE OF THEM PLANNING FOR A FAMILY IS A BIG DECISION TAKE STEPS TOWARD A HEALTHY FUTURE WITH NXGEN GENETIC CARRIER

More information

Symdeko. Symdeko (tezacaftor and ivacaftor) Description

Symdeko. Symdeko (tezacaftor and ivacaftor) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.10 Subject: Symdeko Page: 1 of 5 Last Review Date: June 22, 2018 Symdeko Description Symdeko (tezacaftor

More information

Susanne Schnittger. Workflow of molecular investigations in JAK2-negative MPNs - the Munich experience

Susanne Schnittger. Workflow of molecular investigations in JAK2-negative MPNs - the Munich experience Susanne Schnittger Workflow of molecular investigations in JAK2negative MPNs the Munich experience Cohort single centre experience to apply new markers in a daily diagnostic work flow total: 20,547 cases

More information

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL Supplemental Methods Phenotype Prediction Analyses In order to assess the phylogenetic properties of nssnvs, sequence conservation analysis was conducted using

More information

Genetic Analysis of Allosteric Signaling in RhaR from Escherichia coli and Characterization of the VirF Protein from Shigella flexneri

Genetic Analysis of Allosteric Signaling in RhaR from Escherichia coli and Characterization of the VirF Protein from Shigella flexneri Genetic Analysis of Allosteric Signaling in RhaR from Escherichia coli and Characterization of the VirF Protein from Shigella flexneri By Bria Collette Kettle Submitted to the graduate degree program in

More information

PA Update: Oral Cystic Fibrosis Modulators

PA Update: Oral Cystic Fibrosis Modulators Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

IVACAFTOR THE ISRAELI EXPERIENCE ADI DAGAN MD THE ISRAELI CF CENTER SHEBA MEDICAL CENTER, TEL-HASHOMER

IVACAFTOR THE ISRAELI EXPERIENCE ADI DAGAN MD THE ISRAELI CF CENTER SHEBA MEDICAL CENTER, TEL-HASHOMER IVACAFTOR THE ISRAELI EXPERIENCE ADI DAGAN MD THE ISRAELI CF CENTER SHEBA MEDICAL CENTER, TEL-HASHOMER February 21, 2014 U.S. Food and Drug Administration Approves KALYDECO (ivacaftor) for Use in Eight

More information

Virological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication

Virological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication Virological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication Oscar Blanch-Lombarte Rome, 7-9 June, 2017 European

More information

HCV NS3 Protease Drug Resistance

HCV NS3 Protease Drug Resistance test code: cpt code: 10000 87902 category: Infectious Disease HCV genotypes 1a CODON Simeprevir 1a Boceprevir 1a Telaprevir 1a Paritaprevir 1a Grazoprevir 1a V36A Comment R 3 R 10, 11 R 16 S 24 V36C V36G

More information

Reproductive Medicine & Infertility Associates. I. Reproductive Medicine & Infertility Associates (RMIA)

Reproductive Medicine & Infertility Associates. I. Reproductive Medicine & Infertility Associates (RMIA) Reproductive Medicine & Infertility Associates In compliance with the Federal Consumer Credit Protection Act, we wish to notify you of our policies regarding the payment of statements for services rendered

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Cystic Fibrosis Transmembrane Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Prime Therapeutics

More information

HCV NS3 Protease Drug Resistance

HCV NS3 Protease Drug Resistance test code: cpt code: 10000 87902 category: Infectious Disease HCV genotype 1a CODON Glecaprevir 1a Grazoprevir 1a Paritaprevir 1a Simeprevir 1a Voxilaprevir 1a V36A S 13 R 10 Comment V36C V36G V36I V36L

More information

Result Navigator. Positive Test Result: CDH1. After a positive test result, there can be many questions about what to do next. Navigate Your Results

Result Navigator. Positive Test Result: CDH1. After a positive test result, there can be many questions about what to do next. Navigate Your Results Result Navigator Positive Test Result: CDH1 Positive test results identify a change, or misspelling, of DNA that is known or predicted to cause an increased risk for cancer. DNA is the blueprint of life

More information

genetic carrier screening for cystic fibrosis results you Can trust

genetic carrier screening for cystic fibrosis results you Can trust genetic carrier screening for cystic fibrosis results you Can trust Cystic Fibrosis Carrier Screening Why Carrier Screening for Cystic Fibrosis Is Important? Carrier screening tests help identify individuals

More information

BE PROACTIVE. SCREEN TODAY. PROTECT TOMORROW.

BE PROACTIVE. SCREEN TODAY. PROTECT TOMORROW. BE PROACTIVE. SCREEN TODAY. PROTECT TOMORROW. THE LEADER IN FERTILITY & REPRODUCTIVE GENETIC SCREENING EvolveGene was founded by world leaders in preventive and personalized healthcare, with over 25 years

More information

TECHNICAL NOTICE. The CPT coding in this notice is effective January 1, 2013 and replaces the coding currently in use for these assays

TECHNICAL NOTICE. The CPT coding in this notice is effective January 1, 2013 and replaces the coding currently in use for these assays TECHNICAL NOTICE The CPT coding in this notice is effective January 1, 2013 and replaces the coding currently in use for these assays December 2012 The notation (MAAA) indicates "Multianalyte Assay with

More information

FEP Medical Policy Manual

FEP Medical Policy Manual FEP Medical Policy Manual Effective Date: April 15, 2018 Related Policies: 2.04.59 Genetic Testing for Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies Genetic

More information

Disclosures. Update on Medical Genetics for Family Practitioners. Objectives. Genetic Testing. Types of Genetic Tests. Dogma of Genetics 08/05/2018

Disclosures. Update on Medical Genetics for Family Practitioners. Objectives. Genetic Testing. Types of Genetic Tests. Dogma of Genetics 08/05/2018 Update on Medical Genetics for Family Practitioners Genetic Testing, Newborn Screening, and Direct to Consumer Testing Sandhya Parkash, MD, FRCPC, FCCMG Maritime Medical Genetics Service, IWK Health Centre

More information